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Abstract
The cytogenetic characteristics of osteosarcoma (OS) remain controversial. The establishment of
a new human OS cell line may improve the characterization. We report the establishment of a new
human osteosarcoma cell line, UTOS-1, from a typical osteoblastic OS of an 18-year-old man.
Cultured UTOS-1 cells are spindle-shaped, and have been maintained in vitro for over 50 passages
in more than 2 years. Xenografted UTOS-1 cells exhibit features typical of OS, such as production
of osteoid or immature bone matrix, and proliferation potency in vivo. UTOS-1 also exhibit
morphological and immunohistochemical characteristics typical of osteoblastic OS. Chromosomal
analysis by G-band show 73~85 chromosomes with complicated translocations. Array CGH show
frequent gains at locus DAB2 at chromosome 5q13, CCND2 at 12p13, MDM2 at 12q14.3-q15, FLI
and TOP3A at 17p11.2-p12 and OCRL1 at Xq25, and show frequent losses at HTR1B at 6q13,
D6S268 at 6q16.3-q21, SHGC17327 at 18ptel, and STK6 at 20q13.2-q13.3. The UTOS-1 cell line
may prove useful for biologic and molecular pathogenetic investigations of human OS.
Introduction
Osteosarcoma (OS) is the most common malignant bone
tumor in adolescents and young adults, and is character-
ized by proliferation of tumor cells which produce osteoid
or immature bone matrix. Despite recent advances in mul-
timodality treatment consisting of aggressive adjuvant
chemotherapy and wide local excision, pulmonary metas-
tasis occurs in approximately 40 to 50% of patients with
OS and remains a major cause of fatal outcome [1-3].
There have been several reports describing xenotransplan-
tation models of human OS [4-7], but characterization of
human OS at the molecular cytogenetic level has been
limited [8,9]. We describe the establishment and charac-
terization of a new human OS cell line, designated as
UTOS-1, derived from a conventional osteoblastic OS. In
addition, we analyze chromosomal aberrations and DNA
copy number changes in UTOS-1 by array comparative
genomic hybridization (aCGH).
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Methods
Source of Tumor Cells
An 18-year-old Japanese man noticed swelling and pain of
the left shoulder for 2 months. Radiographs showed a
periosteal reaction and an osteosclerotic change in the
proximal metaphysis of the left humerus. An open biopsy
of this humeral tumor confirmed that it was conventional
osteoblastic OS (Figure 1). Immunohistochemically,
most of the tumor cells were strongly positive for vimen-
tin, alkaline phosphatase (ALP), osteopontin (OP), and
osteocalcin (OC). Despite intensive chemotherapy, the
patient died of lung metastasis 2 months after open
biopsy. The present study was conducted after a human
experimentation review by our ethics committee.
Tumorigenicity in severe combined immunodeficiency 
(SCID) mice
To determine the tumorigenicity of the UTOS-1 cell line in
vivo, 1 × 108 cells were washed, suspended in phosphate-
buffered saline (PBS), and injected subcutaneously into
the leg of 4-week-old male SCID mice (CB-17/Icrscid;
Clea Japan Incorporation, Osaka, Japan). Also, tumor
growth in vivo was measured by calculating tumor volume
based on the measurement of 2 perpendicular diameters
using a caliper [10]. The volume was estimated using the
following formula: 0.5 × L × (S)2, where L and S are the
largest and smallest perpendicular tumor diameters,
respectively.
Establishment of the tumor cell line
Tumor cells were seeded in a 25 cm2 plastic flask (35–
3109; Falcon, Franklin Lakes, NJ, USA) [11]. These cells
were cultured in RPMI 1640 (MP Biomedicals, Solon, OH,
USA), supplemented with 100 mg/ml streptomycin (Meiji
Seika, Tokyo, Japan), 100 U/ml penicillin (Meiji Seika)
and 10% fetal bovine serum (FBS; Funakoshi, Tokyo,
Japan), at 37°C in a humidified atmosphere of 5% CO2
and 95% air. The medium was replaced once per week.
When semiconfluent layers were obtained, the cells were
dispersed with Ca2+- and Mg2+-free PBS containing 0.1%
trypsin and 0.02% EDTA solution, and were then seeded
in new flasks for passage. The configuration of tumor cells
was almost equalized after the 3rd generation. These pro-
cedures were serially performed until the UTOS-1 cell line
was established.
Cell growth in vitro
To determine the doubling time, UTOS-1 cells were
seeded in each well of 96-well dishes (Corning Costar,
Tokyo, Japan) with fresh medium containing 100 μl of
RPMI 1640 with 10% FBS. Cell growth was measured
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay (Cell Counting Kit-8,
Dojindo, Tokyo, Japan) [12]. A volume of 10 μl of MTT
was added to each well, followed by mixing. Plates were
incubated for 3 hours at 37°C in a humidified atmos-
phere of 5% CO2 and 95% air. Formazan levels, which
correspond to the number of viable cells, were quantified
using a microplate reader (model 450; Bio-Rad Laborato-
ries, Hercules, CA, USA) at a wavelength of 450 nm. The
absorbance of each well was evaluated at 6, 12, 24, 48, 72,
96 and 120 hours after seeding. Triplicate wells were used
for each observation.
Immunohistochemistry
Cells were cultured in chamber slides (Lab-Tek; Nalge
Nunc International, Naperville, IL, USA). For the detec-
tion of mesenchymal phenotype, we used 3 monoclonal
antibodies: anti-AE1/AE3, anti-keratin mix, and anti-
vimentin. Also, to assess osteoblastic differentiation, we
used 2 monoclonal antibodies: anti-OP and anti-OC. ALP
activity of UTOS-1 cells was estimated using a modified
version of a cytochemical method described elsewhere
[13], with naphthol AS-MX phosphate-fast blue RR stain-
ing (ALP staining kit; Muto Pure Chemicals Corporation,
Tokyo, Japan).
Cells grown in chamber slides were washed in PBS, fixed
in 4% paraformaldehyde for 15 minutes at room temper-
ature, and then fixed in methanol for 20 minutes at -
20°C. The cells were incubated with each of the primary
antibodies for 24 hours at 4°C. Immunoreaction products
were detected using DAKO envision (DAKO Sytomation,
Carpinteria, CA, USA), and were visualized after adding
diaminobenzidine (DAB; DAKO) as the chromogen.
RNA extraction and reverse-transcription polymerase 
chain reaction (RT-PCR)
Expression of osteoblastic differentiation markers was
assessed using RT-PCR. UTOS-1 cells were grown to con-
Histologic appearance of the original tumor Figure 1
Histologic appearance of the original tumor. Spindle-
shaped tumor cells with atypical nuclei have proliferated with 
formation of osteoid or immature bone matrix (H&E stain). 
Sclae bar: 100 μm.Journal of Experimental & Clinical Cancer Research 2009, 28:26 http://www.jeccr.com/content/28/1/26
Page 3 of 8
(page number not for citation purposes)
fluence, and total cellular RNA was isolated using a TRI-
zol® Reagent (Invitrogen, San Diego, CA, USA). Total RNA
was used as a template for cDNA synthesis using the
SuperScript First-strand Synthesis System (Invitrogen).
PCR was performed to assess expression of ALP, OP and
OC. The oligonucleotide primer sequences and PCR con-
ditions for ALP, OP and OC are shown in Table 1. Ampli-
fied products were analyzed by 2% agarose gel (Cambrex
Bio Science Rockland Incorporation, Rockland, ME, USA)
electrophoresis and ethidium bromide staining (Invitro-
gen). For comparison, Saos-2 [7], which is one of the most
popular OS cell lines, was used as a positive control.
Cytogenetic analysis
For cytogenetic analysis, preparations of metaphase chro-
mosomes from UTOS-1 cells at passage 15 were obtained,
and were banded with Giemsa-trypsin [14]. Karyotypes
were described using the short version of the International
System for Human Cytogenetic Nomenclature [15].
DNA extraction and array CGH
Genomic DNA was extracted from UTOS-1 cells at passage
15. The CGH procedure used was similar to published
standard protocols [16]. Genomic DNA was isolated from
tumor samples using standard procedures including pro-
teinase K digestion and phenol-chloroform extraction.
Array CGH was performed using the GenoSensor Array
300 system, following the manufacturer's instructions
(Vysis, Downers Grove, IL, USA). This array contains the
287 chromosomal regions that are commonly altered in
human cancer, such as telomeres, regions involved in
microdeletions, oncogenes, and tumor suppressor genes.
Tumor DNA (100 ng) was labeled by random priming
with fluorolink cy3-dUTP, and normal reference (control)
DNA was labeled using the same method with cy5-dUTP.
The tumor and control DNAs were then mixed with Cot-
1 DNA (GIBCO-BRL, Gaithersburg, MD, USA), precipi-
tated, and resuspended in microarray hybridization buffer
containing 50% formamide. The hybridization solution
was heated to 80°C for 10 minutes to denature the DNA,
and was then incubated for 1 hour at 37°C. Hybridization
was performed for 72 hours in a moist chamber, followed
by a post-hybridization wash in 50% formamide/2 × SCC
at 45°C. Slides were mounted in phosphate buffer con-
taining 4',6-diamidino-2-phenylindole (DAPI; Sigma, St.
Louis, MO, USA). Fluorescence intensity images were
obtained using the GenoSensor Reader System (Vysis)
according to the manufacturer's instructions. For each
spot, the total intensity of each of the 2 dyes and the ratio
of their intensities were automatically calculated. The
diagnostic cut-off levels representing gains and losses were
set at 1.2 (upper threshold) and 0.8 (lower threshold).
This assay was performed in triplicate, and common aber-
rations were considered to be meaningful aberrations.
Results
Tumor growth in vivo
Approximately 5 weeks after implantation, all SCID mice
had palpable elastic hard nodules with a volume of about
1000 mm3 (Figure 2). The tumor volume was about 4000
mm3 at 6 weeks after implantation, and was > 10,000
mm3 at 8 weeks after implantation. The cut surfaces of
these tumors were solid and white-gray with small
necrotic foci. Histopathologically, the tumors contained
primarily atypical tumor cells, and exhibited formation of
osteoid or immature bone matrix, which is similar in
characteristics to the original tumor (Figure 3).
Cell growth and morphological findings in vitro
UTOS-1 cells were spindle-shaped, contained several
nucleoli, and formed clumps. Two weeks after initial cul-
tivation in primary culture, the tumor cells reached sub-
confluence with some piled-up foci of cells (Figure 4A).
After the cells were serially subcultured for about 3
months, they began to grow rapidly at passage 6 (Figure
4B).
This new cell line has been maintained in vitro for more
than 50 passages over more than 2 years. In the exponen-
tial phase of cell growth, the population-doubling time
was 40 hours (Figure 5).
Table 1: The oligonucleotide primer sequences and PCR conditions for ALP, OP, and OC in this study.
Molecule Primers
(5' to 3')
Strand Size (bp) Conditions
(temperature, cycle number)
ALP ACGTGGCTAAGAATGTCATC
CTGGTAGGCGATGTCCTTA
+
--
475 55°C
35 cycles
OP CCAAGTAAGTCCAACGAAAG
GGTGATGTCCTCGTCTGTA
+
--
347 58°C
45 cycles
OC ATGAGAGCCCTCACACTCCTC
GCCGTAGAAGCGCCGATAGGC
+
--
294 59°C
45 cycles
GAPDH GAAGGTGAAGGTCGGAGTCA
GAAGATGGTGATGGGATTTC
+
--
226 55°C
35 cycle
Abbreviations: ALP, alkaline phosphatase; OP, osteopontin; OC, osteocalcin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.Journal of Experimental & Clinical Cancer Research 2009, 28:26 http://www.jeccr.com/content/28/1/26
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Immunohistochemical and cytochemical findings
All UTOS-1 cells were negative for AE1/AE3 and keratin
mix. Most UTOS-1 cells were positive for vimentin. All
UTOS-1 cells were positive for OP, OC and ALP (Figure
6).
RT-PCR
UTOS-1 cells expressed ALP, OP and OC, which is similar
to the results for Saos-2 (Figure 7).
Cytogenetic findings
A representative karyotype is shown in Figure 8. 50 UTOS-
1 cells exhibited a complex karyotype. The karyotypes of
UTOS-1 cells at passage 15 were similar to those of the
original tumor. The composite karyotypes were as follows:
73~85, Y, -X [7],+Y[10],add(X)(q11)[9],add(X)(q11)
[2],+1[8],del(1)(q11)[9], der(1)add(1)(p11)add(1)
(q42)[9],der(1)add(1)(p22)add(1)(q32)[2],der(1)add(1
)(p32)add(1)(q42)[6],-3[10],-4[3],add(4)(q11)[9],-5
[4],del(5)(p13)[9], +add(6)(q11)[3],der(6)del(6)(p21)
add(6)(q2?)[10],der(6)del(6)(p24)add(6)(q13) ×2,[10]-
7[10],add(7)(p22)[6],der(7)t(7;7)(p22;q22)[10],+8[3],-
9[10],-9[8],add(9)(q22)[9],-10[10],add(10)(p11)[4],add
(10)(q26)[7], der(10)add(10)(p11)add(10)(q26)[3],add
(11)(p11)[9],add(11)(p11)[4], del(11)(p11)[6],-12[5],
der(12)(q21)[6],der(12)add(12)(p11)add(12)(q24)[10]
,der(12)add(12)add(12)[7],-13[10],+14[2], add (14)
(p11)[10],add(14)[2], add(14)(p11)[8],-15[7],add
(15)(p11)[5],add(15)(p11)[4],+16[5], add(16)(p11)[3],
Tumor volume in SCID mice Figure 2
Tumor volume in SCID mice. Tumor volume in logarith-
mic growth phase, ~5 weeks after inoculation. Values are 
expressed as the mean ± standard deviation of triplicate cul-
tures.
Histologic appearance of xenografted tumor in SCID mice Figure 3
Histologic appearance of xenografted tumor in SCID 
mice. A. Xenografted tumor showing features typical of 
osteoblastic osteosarcoma with atypical spindle-shaped cells 
(H&E stain). Scale bar: 100 μm. B. The proliferation of atypi-
cal tumor cells with osteoid formation is shown. Xenografted 
tumor cells resemble original tumor cells. Scale bar: 50 μm.
Morphology under phase-contrast microscopy Figure 4
Morphology under phase-contrast microscopy. A. In 
primary culture, spindle-shaped tumor cells reach subconflu-
ence with some piled-up foci of cells. Scale bar: 100 μm. B. 
At passage 6, the tumor cells begin to grow rapidly. The con-
figuration of tumor cells is equalized after the 6th generation. 
Scale bar: 100 μm.
Tumor cell growth in vitro Figure 5
Tumor cell growth in vitro. UTOS-1 cells begin to grow 
~24 hours after inoculation. The population-doubling time of 
the cells is 40 hours. Values are expressed as the mean ± 
standard deviation of triplicate cultures.Journal of Experimental & Clinical Cancer Research 2009, 28:26 http://www.jeccr.com/content/28/1/26
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add(16)(q24)[2],add(16)(p11)[10],add(16)[4],-17[10],-
17[8],add(17)(q24)[3],?del(17)(p11)[3],-18[5],add(18)
(p11)[9], add(18)(q21)[5],+19[5],add(19)(p11)[9],add
(19)(q13)[8],del(19)(p13)[9],+20[7],add(20)(p11)[7],a
dd(20)(p13)[8],add(20)(q11)[4],+21[8],+21[4],add(21)
(p11)[10],add(21)(p11)[4],add(21)(q22)[7],+22[10],+2
2[7],+22[3],del(22)(q13)[10],del(22)[9],+10~18 mar.
Array CGH
Significant gains of DNA sequences were observed for
locus  DAB2  at chromosome 5q13, CCND2  at 12p13,
MDM2 at 12q14.3-q15, FLI, TOP3A at 17p11.2-p12, and
OCRL1 at Xq25. Significant losses of DNA sequences were
observed for HTR1B  at 6q13, D6S268  at 6q16.3-q21,
SHGC17327 at 18ptel, and STK6 at 20q13.2-q13.3. The
representative aCGH profile is shown in Figure 9.
Discussion
There have been several reports describing xenotransplan-
tation models of human OS [4-7]. In the present study,
the parent tumor, the cultured tumor cells, and the
xenografted tumor exhibited features typical of OS, as
Immunohistochemical findings Figure 6
Immunohistochemical findings. A, B. UTOS-1 cells are 
negative for AE1/AE3 and keratin mix. C, D, E. Most UTOS-
1 cells are positive for vimentin, OP, and OC. F. Staining for 
ALP was performed using a modified cytochemical method. 
ALP activity is visible as blue staining. UTOS-1 cells are 
strongly positive for ALP.
Osteoblast marker expression in UTOS-1 cells Figure 7
Osteoblast marker expression in UTOS-1 cells. The 
expression of several osteoblast markers, including ALP, OP 
and OC, is shown. Saos-2, which is one of the most popular 
OS cell lines, is used as a positive control for osteoblastic 
markers in UTOS-1 cells. These cells express ALP, OP and 
OC, which is similar to Saoa-2.
A representative G-banded karyotype of a UTOS-1 cell Figure 8
A representative G-banded karyotype of a UTOS-1 
cell. Arrows show the abnormal chromosomes.Journal of Experimental & Clinical Cancer Research 2009, 28:26 http://www.jeccr.com/content/28/1/26
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reported previously [15,17]. Cultured UTOS-1 cells have a
spindle shape with several nucleoli, which is similar to the
original tumor cells. Biochemical characteristics of UTOS-
1, such as cell growth rate and osteoblastic activity, have
not changed during the 2 years that they have been main-
tained. Immunohistochemically, the UTOS-1 cells remain
positive for ALP, OP and OC. After implantation from cell
culture into SCID mice, UTOS-1 cells grew in vivo, produc-
ing osteoid resembling that of the original tumor. Abun-
dant osteoid tissue formed in the xenografted tumors and
reimplanted tumors. These findings suggest that UTOS-1
cells have an osteoblastic phenotype and retain the char-
acteristics of the original tumor. The population-doubling
time of UTOS-1 cells in vitro is 40 hours, which is similar
to that of other OS cell lines [4,6,18].
Several reports indicate that OS cells have karyotypes with
multiple numerical rearrangements and complex struc-
tural rearrangements [9,19-21]. Together, the results of
several cytogenetic surveys indicate that OS cells fre-
quently have structural alterations at chromosome bands
1p11-13, 1q11-12, 1q21-22, 11p15, 12p13, 17p11-3,
19q13, and 22q11-13, and frequently have the numerical
chromosome abnormalities +1, -9, -10, -13, and -17. In
UTOS-1 cells, the clonal chromosomal abnormalities that
were detected were triploidies. The chromosomal rear-
rangements that were observed in UTOS-1 involved chro-
mosomes 1q11-12, 11p15, 19q13, and 22q11-13. The
numerical chromosome abnormalities that were observed
in UTOS-1 included +1, -9, -10, -13, and -17. These find-
ings are similar to studies of other OS cell lines [8].
Metaphase CGH studies of OS have identified frequent
gains at chromosome bands 1p32, 1q21, 5p13, 6p12,
8q24, 8cen-q13, 17p11.2, and Xp21, and frequent losses
at bands 6q16, 10p12pter, and 10q22-q26 [22,23].
Recent metaphase CGH studies of OS have focused on
amplifications at chromosomes 8q, 6p, and 17p [22,24].
Advances in mapping resolution of microarray CGH
[25,26] have greatly improved its resolving power, such
that it now provides greater detail than metaphase CGH
regarding the complexity and exact location of genomic
rearrangements leading to copy number imbalances.
In the present study, chromosome 12 showed several dis-
tinct regions of focal amplification, occurring at gains of
CCND2 at 12p13 12q13 and MDM2 at 12q14.3-q15. Pre-
vious CGH studies of OS have revealed abnormalities of
chromosome 12, including gains at bands 12p12-p13
[24], 12q12-q13 [27], and 12q13-q14 [28]. Expression of
the CCND2 gene, which is located at chromosome 12p13,
has been observed in various malignancies, including
prostate cancer and breast cancer [29-31]. CCND2
encodes a protein belonging to the cyclin family of pro-
teins that regulate cyclin-dependent kinase (CDK) kinases
[32]. CDK activity controls the cell cycle G1/S transition
by regulating phosphorylation of the tumor suppressor
protein Rb [33]. These facts suggest that CCND2 controls
proliferation of UTOS-1 tumor cells.
Some studies indicate that 14 to 27% of OS tumors have
abnormal MDM2 expression [34,35]. MDM2 is a target
gene of the transcription factor tumor protein p53 [36].
The encoded protein is a nuclear phosphoprotein that
binds and inhibits transactivation by tumor protein p53,
as part of an autoregulatory negative feedback loop
[37,38]. Overexpression of MDM2  gene can result in
excessive inactivation of tumor protein p53, diminishing
its tumor suppressor function. These findings suggest the
possible involvement of the p53 tumor suppressor gene,
which is associated with development of OS in UTOS-1
cells.
The gain of chromosome band at 17p11.2-p12 has been
observed in approximately 13 to 29% of high-grade OS
[24,39,40]. In UTOS-1 cells, gain of the genes FLI and
TOP3A at chromosome 17p11.2-p12 has been observed.
These findings suggest that multiple gains, including FLI,
TOP3 or other genes close to these candidate oncogenes,
are present at chromosome 17p11.2-p12 and contribute
to OS tumorigenesis [41]. Recent studies indicate that
overexpression of 17p11.2-p12 is associated with p53
degradation [42-44].
In a study of OS using a cDNA array, Squire et al. observed
amplification of the genes MYC, GAS7, and PM1 in OS
cells [45]. Other reports indicate that losses of chromo-
some bands 6q16 and 6q21-q22 occur in high-grade OS
[46]. These findings and those of the present study suggest
that gene losses on chromosome 6q, including HTR1B
and D6S268, contribute to OS tumorigenesis.
One of the most remarkable breakpoint clusters that have
been found in OS tumors was detected on chromosome
Genetic instability analyzed by aCGH Figure 9
Genetic instability analyzed by aCGH. The line in the 
middle (gray) is the baseline ratio (1.0); The upper (red) and 
lower (green) bars in each frame indicate losses and gains, 
respectively. The arrow shows the axes of X and Y chromo-
somes.Journal of Experimental & Clinical Cancer Research 2009, 28:26 http://www.jeccr.com/content/28/1/26
Page 7 of 8
(page number not for citation purposes)
20 by spectral karyotyping (SKY) analysis [47]. Chromo-
some 20 is one of the smaller chromosomes, suggesting
that it is particularly vulnerable to structural rearrange-
ment. However, there is little evidence that chromosome
20 is frequently involved in chromosomal imbalances
[26,28]. In the present study, the only loss that involved
chromosome 20 occurred at band 20q13.2-q13.3. Many
chromosomal changes have been observed in CGH stud-
ies of high-grade OS [46]. Reports indicate that the genes
involved in OS tumorigenesis include DAB2 (at chromo-
some 5q13), OCRL1  (at Xq25), and SHGC17327  (at
18ptel). However, many of these genes were not previ-
ously known to be associated with OS tumorigenesis.
In conclusion, we have isolated and characterized a new
permanent human cell line, UTOS-1, established from an
osteoblastic OS. This cell line retains the morphology,
osteoblastic activities and cytogenetic characteristics of
the original tumor in vitro. The UTOS-1 cell line is useful
for biologic and molecular pathogenetic studies of human
OS.
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